SLNSW-Olaparib in patients with recurrent high-grade se...-TN_cdi_proquest_journals_887160920

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Full title: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Author/creator: Gelmon, Karen A, Prof, Tischkowitz, Marc, MD, Mackay, Helen, MD, Swenerton, Kenneth, MD, Robidoux, André, Prof, Tonkin, Katia, Prof, Hirte, Hal, MD, Huntsman, David, Prof, Clemons, Mark, MD, Gilks, Blake, Prof, Yerushalmi, Rinat, MD, Macpherson, Euan, MSc, Carmichael, James, MD, Oza, Amit, Prof.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_887160920

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_887160920

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

    Record identifier

    TN_cdi_proquest_journals_887160920

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_887160920

    Share

    Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_887160920

    Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

    Full title

    Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

    Author / Creator

    Gelmon, Karen A, Prof ; Tischkowitz, Marc, MD ; Mackay, Helen, MD ; Swenerton, Kenneth, MD ; Robidoux, André, Prof ; Tonkin, Katia, Prof ; Hirte, Hal, MD ; Huntsman, David, Prof ; Clemons, Mark, MD ; Gilks, Blake, Prof ; Yerushalmi, Rinat, MD ; Macpherson, Euan, MSc ; Carmichael, James, MD ; Oza, Amit, Prof

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2011, Vol.12 (9), p.852-861

    Record Identifier

    TN_cdi_proquest_journals_887160920

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biomarkers, Tumor - analysis BRCA1 Protein - genetics BRCA2 Protein - genetics Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - enzymology Breast Neoplasms - genetics Breast Neoplasms - mortality Breast Neoplasms - pathology Canada Cancer Carcinoma - drug therapy Carcinoma - enzymology Carcinoma - genetics Carcinoma - mortality Carcinoma - secondary Care and treatment Cell Differentiation Disease-Free Survival Diseases Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Female Gene mutations Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Middle Aged Mutation Neoplasm Recurrence, Local Oncology, Experimental Ovarian Neoplasms - drug therapy Ovarian Neoplasms - enzymology Ovarian Neoplasms - genetics Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Phthalazines - administration & dosage Phthalazines - adverse effects Phthalazines - therapeutic use Piperazines - administration & dosage Piperazines - adverse effects Piperazines - therapeutic use Poly(ADP-ribose) Polymerase Inhibitors Poly(ADP-ribose) Polymerases - metabolism Receptor, ErbB-2 - analysis Receptors, Estrogen - analysis Receptors, Progesterone - analysis Relapse Time Factors Treatment Outcome

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_887160920

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_887160920

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections